2017
Mycobacterium grossiae sp. nov., a rapidly growing, scotochromogenic species isolated from human clinical respiratory and blood culture specimens
Paniz-Mondolfi AE, Greninger AL, Ladutko L, Brown-Elliott BA, Vasireddy R, Jakubiec W, Vasireddy S, Wallace RJ, Simmon KE, Dunn BE, Jackoway G, Vora SB, Quinn KK, Qin X, Campbell S. Mycobacterium grossiae sp. nov., a rapidly growing, scotochromogenic species isolated from human clinical respiratory and blood culture specimens. International Journal Of Systematic And Evolutionary Microbiology 2017, 67: 4345-4351. PMID: 28984546, DOI: 10.1099/ijsem.0.002216.Peer-Reviewed Original ResearchConceptsSevere chronic obstructive pulmonary diseasePost-bone marrow transplantChronic obstructive pulmonary diseaseSusceptibility testingDoxycycline/minocyclineObstructive pulmonary diseaseBone marrow transplantMycobacterium avium complexBlood culture specimensLaboratory Standards InstituteAntimicrobial susceptibility testingScotochromogenic speciesTuberculosis exposurePulmonary diseaseMarrow transplantMycobacterium wolinskyiCulture specimensAvium complexIntermediate susceptibilityGas-liquid chromatography analysisClinical sourcesStandards InstituteIsolatesMycobacteriaBiochemical profiling
2010
Biomarker-Assisted Dose Selection for Safety and Efficacy in Early Development of PNU-100480 for Tuberculosis
Wallis RS, Jakubiec W, Kumar V, Bedarida G, Silvia A, Paige D, Zhu T, Mitton-Fry M, Ladutko L, Campbell S, Miller PF. Biomarker-Assisted Dose Selection for Safety and Efficacy in Early Development of PNU-100480 for Tuberculosis. Antimicrobial Agents And Chemotherapy 2010, 55: 567-574. PMID: 21078950, PMCID: PMC3028776, DOI: 10.1128/aac.01179-10.Peer-Reviewed Original ResearchMeSH KeywordsAcetamidesAdolescentAdultAnimalsAntitubercular AgentsArea Under CurveDose-Response Relationship, DrugDrug Administration ScheduleHumansLinezolidMicrobial Sensitivity TestsMiddle AgedMycobacterium tuberculosisOxazolidinonesPyrazinamideRatsSerum Bactericidal TestTreatment OutcomeTuberculosisYoung AdultConceptsPNU-100480Whole-blood bactericidal activityMultiple ascending dosesDays of dosingSerious global health threatWhole blood culturesBactericidal activityGlobal health threatM. tuberculosis growthAscending dosesSixth cohortNew tuberculosis treatmentsPlasma drugTuberculosis treatmentPlasma concentrationsSafety signalsHealthy volunteersDose selectionRoutine safety testsNew treatmentsDay 27TuberculosisMycobacterium tuberculosisDosesHealth threat
2006
Measurement of Serum d-Arabinitol/Creatinine Ratios for Initial Diagnosis and for Predicting Outcome in an Unselected, Population-Based Sample of Patients with Candida Fungemia
Yeo SF, Huie S, Sofair AN, Campbell S, Durante A, Wong B. Measurement of Serum d-Arabinitol/Creatinine Ratios for Initial Diagnosis and for Predicting Outcome in an Unselected, Population-Based Sample of Patients with Candida Fungemia. Journal Of Clinical Microbiology 2006, 44: 3894-3899. PMID: 16957030, PMCID: PMC1698297, DOI: 10.1128/jcm.01045-06.Peer-Reviewed Original ResearchConceptsCandida fungemiaUnselected patientsCreatinine ratioInitial diagnosisMicroM/First positive blood cultureD-arabinitol/creatinine ratioHigh-risk groupSample of patientsPositive blood culturesUseful diagnostic markerFungemia patientsFungemic patientsBlood culturesPredicting OutcomePatientsFungemiaHealthy adultsDiagnostic markerPrognostic purposesMore daysSame dayC. parapsilosisEnzymatic fluorometric assayCancer